BioCentury
ARTICLE | Clinical News

Ganetespib: Phase II started

August 15, 2011 7:00 AM UTC

Synta disclosed in its 2Q11 earnings that investigators at the Dana-Farber Cancer Institute began an open-label, U.S. Phase II trial to compare 200 mg/m 2 IV ganetespib given weekly for the first 3 w...